Celldex Therapeutics (CLDX) Institutional Ownership

Of the 158 institutional investors that purchased Celldex Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Wellington Management Group LLP ($4.01M), Braidwell LP ($1.86M), Vestal Point Capital LP ($1.86M), Deep Track Capital LP ($1.54M), Point72 Asset Management L.P. ($1.50M), ADAR1 Capital Management LLC ($1.14M), and Millennium Management LLC ($1.04M).

Institutional investors have bought a total of 18,097,567 shares in the last 24 months. This purchase volume represents approximately $471.10M in transactions.

Of the 61 institutional investors that sold Celldex Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Eventide Asset Management LLC ($2.62M), Woodline Partners LP ($1.30M), Commodore Capital LP ($885K), Vestal Point Capital LP ($585K), UBS Group AG ($514.78K), Price T Rowe Associates Inc. MD ($342.81K), and Polar Capital Holdings Plc ($292.27K).

Institutional investors have sold a total of 8,822,661 shares in the last 24 months. This volume of shares sold represents approximately $218.69M in transactions.